


FIG. 1

B




FIG. 1 (cont)




FIG. 1 (cont)

A



24 h. after i.n. administration
Tumor-bearing mice
%ID/g
70
0
65
62.3
62.3
45.4
33.6

FIG. 2

B

24 h. after i.n. administration
Healthy control




FIG. 2 (cont)

C



Tumor-bearing mice
% Intranasal Dose
60
40
20
0
0.5
4.0
24.0
Time (h)
Lung
Kidney
Liver
Gut
Healthy mice
% Intranasal Dose
50
40
30
20
10
0
0.5
4.0
24.0
48.0
Time (h)
Lung
Kidney
Liver
Gut

FIG. 2 (cont)



A
Vehicle
Omomyc^CPP-AF660
side 1
side 2
0,7
2.0
2.0
2.0
1.1
2.0
1.5
1.0
0.5
x10^9
Radiant Efficiency
(p/sec/cm²/sr)
(µWcm²)
B
Vehicle
Omomyc^CPP-AF660
FLI
Visible
0.4
0.6
0.5
2.0
2.0
1.0
0.7
0.5
0.5
0.5
2.0
1.5
1.0
0.5
x10^8
Radiant Efficiency
(p/sec/cm²/sr)
(µWcm²)

FIG. 3



% Injected Dose/g tissue
20
15
10
5
1.0
0.5
0.0
HEART
LUNG
LIVER
SPLEEN
KIDNEY
MUSCLE
BONE
FAT
STOMACH
INTESTINE
BRAIN
TUMOR

FIG. 4